Product Description
NeuroSense Therapeutics is developing PrimeC as a treatment for ALS. (Sourced from: https://www.neurosense-tx.com/pipeline/)
Mechanisms of Action: DNA Gyrase Inhibitor, COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: Orphan Drug - Amyotrophic Lateral Sclerosis *
Approval Status: Not Approved
Approved Countries: India | Pakistan
Approved Indications: None
Company: NeuroSense Therapeutics
Company Location: Europe
Company Founding Year: 2017
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - NeuroSense Therapeutics presented P2 Amyotrophic Lateral Sclerosis results on 2026-03-19 for PrimeC
- Clinical Outcomes Reported - NeuroSense Therapeutics presented P2 Amyotrophic Lateral Sclerosis results on 2026-03-16 for PrimeC
- Clinical Outcomes Reported - NeuroSense Therapeutics presented P2 Amyotrophic Lateral Sclerosis results on 2026-03-09 for PrimeC
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2022-002185-32 |
PARADIGM | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2024-10-29 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/11/2026 |
News Article |
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS |
|
04/06/2026 |
News Article |
NeuroSense Granted Brazilian Patent Covering PrimeC Composition |
|
04/03/2026 |
News Article |
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements |
|
03/24/2026 |
News Article |
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout |